Transcriptomic And Metabolomic Profiling Identifies Calcium-Dependent Signaling Mechanisms As A Novel And Exploitable Target To Overcome Anti-Cd20 Resistance In Non-Hodgkin Lymphoma (Nhl)

Introduction: Anti-CD20 antibody drugs such as rituximab (RTX) and obinutuzumab (OBZ) are used ubiquitously in the treatment of B cell NHL. However, therapeutic resistance to anti-CD20 antibodies occurs quite commonly, especially in indolent NHL. Known mechanisms of resistance include loss of CD20 expression, poor immunoreactivity and dysfunctional apoptotic responses. However, few therapeutic strategies have been established to overcome resistance. Identification of new, targetable anti-CD20 resistance mechanisms are needed.